Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Phosphodiesterase 10 inhibitors: new disease modifying drugs for Parkinson's disease?

García AM, Redondo M, Martinez A, Gil C.

Curr Med Chem. 2014 Apr;21(10):1171-87. Review.

PMID:
24372206
[PubMed - indexed for MEDLINE]
2.

Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.

Giampà C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR.

PLoS One. 2010 Oct 15;5(10):e13417. doi: 10.1371/journal.pone.0013417.

PMID:
20976216
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.

Leuti A, Laurenti D, Giampà C, Montagna E, Dato C, Anzilotti S, Melone MA, Bernardi G, Fusco FR.

Neurobiol Dis. 2013 Apr;52:104-16. doi: 10.1016/j.nbd.2012.11.016. Epub 2012 Dec 7.

PMID:
23220622
[PubMed - indexed for MEDLINE]
4.

Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease.

Kleiman RJ, Kimmel LH, Bove SE, Lanz TA, Harms JF, Romegialli A, Miller KS, Willis A, des Etages S, Kuhn M, Schmidt CJ.

J Pharmacol Exp Ther. 2011 Jan;336(1):64-76. doi: 10.1124/jpet.110.173294. Epub 2010 Oct 5.

PMID:
20923867
[PubMed - indexed for MEDLINE]
Free Article
5.

Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.

Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, Schmidt CJ.

Neuropharmacology. 2006 Aug;51(2):386-96. Epub 2006 Jun 15.

PMID:
16780899
[PubMed - indexed for MEDLINE]
6.

Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.

Menniti FS, Chappie TA, Humphrey JM, Schmidt CJ.

Curr Opin Investig Drugs. 2007 Jan;8(1):54-9. Review.

PMID:
17263185
[PubMed - indexed for MEDLINE]
7.

PDE10A inhibitors: novel therapeutic drugs for schizophrenia.

Kehler J, Nielsen J.

Curr Pharm Des. 2011;17(2):137-50. Review.

PMID:
21355834
[PubMed - indexed for MEDLINE]
8.

N-Methylanilide and N-methylbenzamide derivatives as phosphodiesterase 10A (PDE10A) inhibitors.

Kilburn JP, Kehler J, Langgård M, Erichsen MN, Leth-Petersen S, Larsen M, Christoffersen CT, Nielsen J.

Bioorg Med Chem. 2013 Oct 1;21(19):6053-62. doi: 10.1016/j.bmc.2013.07.030. Epub 2013 Jul 23.

PMID:
23978358
[PubMed - indexed for MEDLINE]
9.

PDE10A inhibitors: an assessment of the current CNS drug discovery landscape.

Chappie T, Humphrey J, Menniti F, Schmidt C.

Curr Opin Drug Discov Devel. 2009 Jul;12(4):458-67. Review.

PMID:
19562642
[PubMed - indexed for MEDLINE]
10.

Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development.

Jeon YH, Heo YS, Kim CM, Hyun YL, Lee TG, Ro S, Cho JM.

Cell Mol Life Sci. 2005 Jun;62(11):1198-220. Review.

PMID:
15798894
[PubMed - indexed for MEDLINE]
11.

Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A.

Strick CA, James LC, Fox CB, Seeger TF, Menniti FS, Schmidt CJ.

Neuropharmacology. 2010 Feb;58(2):444-51. doi: 10.1016/j.neuropharm.2009.09.008. Epub 2009 Sep 16.

PMID:
19765598
[PubMed - indexed for MEDLINE]
12.

Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.

Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD 3rd, Williams RD, Verhoest PR, Menniti FS.

J Pharmacol Exp Ther. 2008 May;325(2):681-90. doi: 10.1124/jpet.107.132910. Epub 2008 Feb 20.

PMID:
18287214
[PubMed - indexed for MEDLINE]
Free Article
13.

N-Acylhydrazones as inhibitors of PDE10A.

Gage JL, Onrust R, Johnston D, Osnowski A, Macdonald W, Mitchell L, Urögdi L, Rohde A, Harbol K, Gragerov S, Dormán G, Wheeler T, Florio V, Cutshall NS.

Bioorg Med Chem Lett. 2011 Jul 15;21(14):4155-9. doi: 10.1016/j.bmcl.2011.05.100. Epub 2011 Jun 2.

PMID:
21696955
[PubMed - indexed for MEDLINE]
14.

Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.

Hebb AL, Robertson HA, Denovan-Wright EM.

Neuroscience. 2004;123(4):967-81.

PMID:
14751289
[PubMed - indexed for MEDLINE]
15.

The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.

Smith SM, Uslaner JM, Cox CD, Huszar SL, Cannon CE, Vardigan JD, Eddins D, Toolan DM, Kandebo M, Yao L, Raheem IT, Schreier JD, Breslin MJ, Coleman PJ, Renger JJ.

Neuropharmacology. 2013 Jan;64:215-23. doi: 10.1016/j.neuropharm.2012.06.013. Epub 2012 Jun 27.

PMID:
22750078
[PubMed - indexed for MEDLINE]
16.

Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice.

Hebb AL, Robertson HA, Denovan-Wright EM.

Eur Neuropsychopharmacol. 2008 May;18(5):339-63. Epub 2007 Oct 29.

PMID:
17913473
[PubMed - indexed for MEDLINE]
17.

Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum.

Nishi A, Kuroiwa M, Miller DB, O'Callaghan JP, Bateup HS, Shuto T, Sotogaku N, Fukuda T, Heintz N, Greengard P, Snyder GL.

J Neurosci. 2008 Oct 15;28(42):10460-71. doi: 10.1523/JNEUROSCI.2518-08.2008.

PMID:
18923023
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.

Chappie TA, Humphrey JM, Allen MP, Estep KG, Fox CB, Lebel LA, Liras S, Marr ES, Menniti FS, Pandit J, Schmidt CJ, Tu M, Williams RD, Yang FV.

J Med Chem. 2007 Jan 25;50(2):182-5.

PMID:
17228859
[PubMed - indexed for MEDLINE]
19.

Role of phosphodiesterases in neurological and psychiatric disease.

Hebb AL, Robertson HA.

Curr Opin Pharmacol. 2007 Feb;7(1):86-92. Epub 2006 Nov 20. Review.

PMID:
17113826
[PubMed - indexed for MEDLINE]
20.

Chemotherapeutic potential of phosphodiesterase inhibitors.

Perry MJ, Higgs GA.

Curr Opin Chem Biol. 1998 Aug;2(4):472-81. Review.

PMID:
9736920
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk